Double-blind cross-over trial of oral sodium cromoglycate in patients with irritable bowel syndrome due to food intolerance
- PMID: 1742648
- DOI: 10.1111/j.1365-2222.1991.tb00848.x
Double-blind cross-over trial of oral sodium cromoglycate in patients with irritable bowel syndrome due to food intolerance
Abstract
Twenty patients with irritable bowel syndrome due to food intolerance were randomized to either oral sodium cromoglycate or placebo in a double-blind cross-over trial. The study consisted of treatment with either sodium cromoglycate or placebo for 8 weeks, followed by the cross-over treatment for 8 further weeks. Patients were allowed to eat the offending foods during the study. Eighteen patients completed the study. Analysis of patients' diary card scores showed a statistically significant difference in favour of sodium cromoglycate. There was a long carry-over effect in the active-placebo order group. Therefore oral sodium cromoglycate seems to be a useful treatment in patients with irritable bowel syndrome and proven food intolerance.
Similar articles
-
Oral cromolyn sodium in comparison with elimination diet in the irritable bowel syndrome, diarrheic type. Multicenter study of 428 patients.Scand J Gastroenterol. 1995 Jun;30(6):535-41. doi: 10.3109/00365529509089786. Scand J Gastroenterol. 1995. PMID: 7569760 Clinical Trial.
-
Efficacy of oral disodium cromoglycate in patients with irritable bowel syndrome and positive skin prick tests to foods.Lancet. 1986 Jan 25;1(8474):207-8. doi: 10.1016/s0140-6736(86)90673-2. Lancet. 1986. PMID: 2868223 No abstract available.
-
Double-blind crossover trial with oral sodium cromoglycate in children with atopic dermatitis due to food allergy.Ann Allergy. 1986 Dec;57(6):433-8. Ann Allergy. 1986. PMID: 3098141 Clinical Trial.
-
Irritable bowel syndrome and food intolerance.Practitioner. 1994 Jul;238(1540):499-502, 504. Practitioner. 1994. PMID: 7937502 Review. No abstract available.
-
Dietary fiber, food intolerance, and irritable bowel syndrome.Nutr Rev. 1990 Sep;48(9):343-6. doi: 10.1111/j.1753-4887.1990.tb02977.x. Nutr Rev. 1990. PMID: 1965739 Review. No abstract available.
Cited by
-
Intestinal Mucosal Mast Cells: Key Modulators of Barrier Function and Homeostasis.Cells. 2019 Feb 8;8(2):135. doi: 10.3390/cells8020135. Cells. 2019. PMID: 30744042 Free PMC article. Review.
-
Mast cell mediation of visceral sensation and permeability in irritable bowel syndrome.Neurogastroenterol Motil. 2022 Jul;34(7):e14339. doi: 10.1111/nmo.14339. Epub 2022 Mar 21. Neurogastroenterol Motil. 2022. PMID: 35315179 Free PMC article. Review.
-
Eosinophils and mast cells as therapeutic targets in pediatric functional dyspepsia.World J Gastrointest Pharmacol Ther. 2013 Nov 6;4(4):86-96. doi: 10.4292/wjgpt.v4.i4.86. World J Gastrointest Pharmacol Ther. 2013. PMID: 24199024 Free PMC article. Review.
-
The Effect of Dietary Intervention on Irritable Bowel Syndrome: A Systematic Review.Clin Transl Gastroenterol. 2015 Aug 20;6(8):e107. doi: 10.1038/ctg.2015.21. Clin Transl Gastroenterol. 2015. PMID: 26291435 Free PMC article.
-
A Pilot Study of Ketotifen in Patients Aged 8-17 Years with Functional Dyspepsia Associated with Mucosal Eosinophilia.Paediatr Drugs. 2024 Jul;26(4):451-457. doi: 10.1007/s40272-024-00628-8. Epub 2024 May 21. Paediatr Drugs. 2024. PMID: 38771467 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical